samedan logo
 
 
spacer
home > white papers > e-tools enhance clinical trial performance - e-novex
WHITE PAPERS
logo_e-novext.jpg

e-novex

phone +32 3 292 63 20
email info@e-novex.com
web http://www.e-novex.com/
email e-novex, Justitiestraat 6B, 2018 Antwerp, Belgium

e-tools enhance clinical trial performance

In today’s ever-evolving medical business, technological changes require innovation to meet growing market demands and to bring about advances in the industry. One such development currently taking place in the field of clinical research is how e-tools are initiating a boost in the productivity of clinical trials.
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Avacta Announces FDA Approval of its Investigational New Drug (IND) Application for AVA6000

Cambridge and Wetherby, UK, 29 November 2021: Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for AVA6000. This will allow the Group to expand its Phase 1 clinical trial, ALS-6000-101, into clinical trial sites in the United States.
More info >>


White Papers


©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement